Lung cancer risk in relation to mephenytoin hydroxylation activity

Pharmacogenetics

Volumn 7, Issue 2, 1997, Pages 157-159

  Benhamou, Simone ^a   Bouchardy, Christine ^b   Dayer, Pierre ^c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b GENEVA CANCER REGISTRY   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

CYP2C19 activity; Epidemiology; Lung cancer; Smoking

Indexed keywords

CARCINOGEN; CYTOCHROME P450; DEXTROMETHORPHAN; MEPHENYTOIN;

ADULT; AGED; ARTICLE; CANCER RISK; CIGARETTE SMOKING; CONTROLLED STUDY; DOSE RESPONSE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG MIXTURE; FEMALE; GENETIC VARIABILITY; HUMAN; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TOBACCO;

ADULT; ARYL HYDROCARBON HYDROXYLASES; CARCINOMA; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FRANCE; HUMANS; HYDROXYLATION; LUNG NEOPLASMS; MALE; MEPHENYTOIN; MIDDLE AGED; MIXED FUNCTION OXYGENASES; RISK FACTORS; SMOKING;

NICOTIANA TABACUM;

EID: 0030965011     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199704000-00011     Document Type: Article

References (11)

1. Ayesh R, Idle JR. Evaluation of drug oxidation phenotypes in the biochemical epidemiology of lung cancer risk. In: Microsomes and drug oxidations (Boobis AR, Caldwell J, De Matteis F, and Elcombe CR, eds). London: Taylor & Francis, 1985: 340-346.
2. Benhamou S, Bouchardy C, Paoletti C, Dayer P. Effects of CYP2D6 activity and tobacco on larynx cancer risk. Cancer Epidemiology, Biomarkers & Prev 1996: 5, 683-686.
3. Bouchardy C, Benhamou S, Dayer P. The effect of tobacco on lung cancer risk depends on CYP2D6 activity. Cancer Res 1996: 56, 251-253.
4. Breslow NE, Day NE. The analysis of case-control studies. In: Statistical methods in cancer research. IARC Scientific Publications, Vol 1, No 32. Lyon. France: International Agency for Research on Cancer. 1980: 192-242.
5. Caraco Y, Wilkinson GR, Wood AJJ. Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole. Clin Pharmacol Ther 1996: 60, 396-404.
6. Guttendorf RJ, Britto M, Blouin RA, Foster TS, John W, Pittman KA, Wedlund PJ. Rapid screening for polymorphism in dextromethorphan and mephenytoin metabolism. Br J Clin Pharmacol 1990: 29, 373-380.
7. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans Tobacco Smoking, Vol. 38. Lyon. France: International Agency for Research on Cancer: 1986.
8. Jacqz E, Dulac H, Mathieu H. Phenotyping polymorphic drug metabolism in the French Caucasian population. Eur J Clin Pharmacol 1988: 35, 167-171.
9. Kaisary A, Smith P, Jacqz E, McAllister CB, Wilkinson GR, Ray WA, Branch RA. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res 1987: 47, 5488-5493.
10. Meier U, Dayer P, Malé J, Kronbach T, Meyer U. Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo. Clin Pharmacol Ther 1985: 38, 488-494.
11. Wolf C, Smith C, Forman D. Metabolic polymorphism in carcinogen metabolizing enzymes and cancer susceptibility. Br Med J 1994: 50, 718-731.